BR112014009789A2 - cisteamina no tratamento da doença fibrótica - Google Patents

cisteamina no tratamento da doença fibrótica

Info

Publication number
BR112014009789A2
BR112014009789A2 BR112014009789A BR112014009789A BR112014009789A2 BR 112014009789 A2 BR112014009789 A2 BR 112014009789A2 BR 112014009789 A BR112014009789 A BR 112014009789A BR 112014009789 A BR112014009789 A BR 112014009789A BR 112014009789 A2 BR112014009789 A2 BR 112014009789A2
Authority
BR
Brazil
Prior art keywords
cysteamine
treatment
fibrotic disease
fibrotic
disease
Prior art date
Application number
BR112014009789A
Other languages
English (en)
Portuguese (pt)
Inventor
A Eddy Allison
M Okamura Daryl
Original Assignee
Seattle Children's Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Children's Res Inst filed Critical Seattle Children's Res Inst
Publication of BR112014009789A2 publication Critical patent/BR112014009789A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014009789A 2011-10-26 2011-10-26 cisteamina no tratamento da doença fibrótica BR112014009789A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/057935 WO2013062544A1 (en) 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease

Publications (1)

Publication Number Publication Date
BR112014009789A2 true BR112014009789A2 (pt) 2017-04-25

Family

ID=48168215

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009789A BR112014009789A2 (pt) 2011-10-26 2011-10-26 cisteamina no tratamento da doença fibrótica

Country Status (7)

Country Link
US (2) US9468612B2 (enExample)
AU (1) AU2011379972B2 (enExample)
BR (1) BR112014009789A2 (enExample)
CA (1) CA2853484C (enExample)
IN (1) IN2014DN03049A (enExample)
MX (1) MX2014004994A (enExample)
WO (1) WO2013062544A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016288230A1 (en) 2015-07-02 2018-01-25 Horizon Orphan Llc ADO-resistant cysteamine analogs and uses thereof
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US10155948B2 (en) * 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US20200093764A1 (en) * 2017-02-07 2020-03-26 Children's Hospital Medical Center Treatment of asthma with cysteamine
CN118924717A (zh) 2017-09-20 2024-11-12 硫创治疗公司 用于治疗半胱胺敏感性病症的方法
US10828372B2 (en) 2017-11-10 2020-11-10 Wisconsin Alumni Research Foundation Compositions and methods for the inhibition of fibrosis
US20220177918A1 (en) * 2019-04-12 2022-06-09 The Regents Of The University Of California Methods for treating inherited eye defects
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
FI906411A7 (fi) 1988-06-28 1990-12-27 La Jolla Cancer Res Foundation Solujen lisääntymisen esto Decorinilla
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0494264B1 (en) 1989-09-29 1997-06-18 La Jolla Cancer Research Foundation Inhibiting transforming growth factor to prevent accumulation of extracellular matrix
CA2068204C (en) 1989-11-22 2002-02-12 Arthur Levinson Latency associated peptides and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5554655A (en) 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
CA2123418A1 (en) 1991-11-14 1993-05-27 Erkki I. Ruoslahti Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
JPH08504763A (ja) 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド 治療薬としてのＴＧＦ−βレセプターフラグメントの使用
CA2147754A1 (en) 1992-10-30 1994-05-11 Michelle Letarte Compositions and methods for modifying the regulatory activity of tgf- .beta.
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
ATE211762T1 (de) 1993-04-30 2002-01-15 Biognostik Ges Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
ATE208494T1 (de) 1994-05-04 2001-11-15 Mount Sinai Hospital Corp Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
CA2232682A1 (en) 1996-04-30 1997-11-06 Susan M. Richards Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
WO1998017304A1 (en) 1996-10-25 1998-04-30 Johnson & Johnson Medical, Inc. Anti-fibrotic agent assay
TR199902878T2 (xx) 1997-04-18 2000-02-21 Biogen,Inc. Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
DE60203263T2 (de) 2001-02-02 2006-02-09 Smithkline Beecham Corp. Pyrazolderivate gegen tgf überexprimierung
US20040097502A1 (en) 2001-02-02 2004-05-20 Gellibert Francoise Jeanne Pyrazoles as tgf inhibitors
ES2289116T3 (es) 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005530800A (ja) 2002-05-15 2005-10-13 スミスクライン・ビーチャム・コーポレイション ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール
US20040038856A1 (en) 2002-05-17 2004-02-26 Sarvajit Chakravarty Treatment of fibroproliferative disorders using TGF-beta inhibitors
CA2494367A1 (en) 2002-07-25 2004-02-05 Scios Inc. Methods for improvement of lung function using tgf-.beta. inhibitors
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
AU2003272324A1 (en) 2002-09-10 2004-04-30 Scios Inc. INHIBITORS OF TFGBeta
EP1543001B1 (en) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
AU2003291149A1 (en) 2002-11-22 2004-06-18 Scios, Inc. USE OF TFG-Beta INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
JP2006524633A (ja) 2002-11-22 2006-11-02 サイオス・インコーポレーテツド β−アドレナリン作動性経路における病理学的変化を打ち消すための方法
WO2004048381A2 (en) 2002-11-22 2004-06-10 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
AU2003290734A1 (en) 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
WO2004056352A1 (en) 2002-12-19 2004-07-08 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
EP1608631A4 (en) 2003-03-28 2008-08-20 Scios Inc BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
KR20070007055A (ko) 2003-12-24 2007-01-12 사이오스 인코퍼레이티드 Ｔｇｆ-베타 억제제를 이용한 악성 신경교종의 치료법
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
DE102004019253A1 (de) 2004-04-16 2005-11-10 Codewrights Gmbh Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
EP1786803A1 (en) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
CA2578630A1 (en) 2004-08-31 2006-03-09 Wen-Cherng Lee Pyrimidinylimidazoles as tgf-beta inhibitors
US7511056B2 (en) 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
MX382184B (es) 2006-01-27 2025-03-13 Univ California Cisteamina recubierta entericamente, cistamina y derivados de ellas.
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
ES2417179T3 (es) * 2007-11-30 2013-08-06 The Regents Of The University Of California Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina

Also Published As

Publication number Publication date
US9468612B2 (en) 2016-10-18
US20140275279A1 (en) 2014-09-18
AU2011379972A1 (en) 2014-05-15
AU2011379972B2 (en) 2016-05-12
CA2853484C (en) 2018-08-21
US20170165207A1 (en) 2017-06-15
MX2014004994A (es) 2014-08-27
CA2853484A1 (en) 2013-05-02
IN2014DN03049A (enExample) 2015-05-15
WO2013062544A1 (en) 2013-05-02
US9925154B2 (en) 2018-03-27

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
LT2707030T (lt) Vėžio gydymas
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
BR112013032887A2 (pt) cateter
EP2692387A4 (en) CATHETER ARRANGEMENT
DK2539015T3 (da) Nethindeprotese
HUE046667T2 (hu) Rák kombinatív kezelése
IL233089A0 (en) Methods for improving medical therapies
BR112014012880A2 (pt) tratamento imunogênico do câncer
IL232262A0 (en) Therapeutic agents and uses thereof
EP2913047A4 (en) Pulmonary disease-specific therapeutic agent
DK2701697T3 (da) Oxidative nethindesygdomme
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
BR112014004434A2 (pt) cateter biocompatível
PT2750709T (pt) Tratamento da caquexia
CY2020015I2 (el) Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα
EP2695154A4 (en) PROVIDING A COMPUTER-BASED LANGUAGE THERAPY
EP2780012A4 (en) Methods of treatment with deferiprone
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
DK2931296T3 (da) Sygdomsbehandling, der involverer mucin
HRP20180685T1 (hr) Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo
CO6880064A2 (es) Métodos terapéuticos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]